


Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
Data presented at EASL Congress 2023
alfapump was effective…

Poolbeg Pharma Plc – Oral Vaccine Programme Moves Forward
Next Generation Oral Vaccine Programme Advancing Through Non-Dilutive…

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

Novo Holdings to acquire Ellab
Novo Holdings A/S, a leading global life sciences investor, today…

Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer
Professor Dmochowski is a world leading key opinion leader…

Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
Ghent, Belgium – 16 June 2023 – Sequana Medical NV (Euronext…

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program
Dr. Favre brings extensive experience in gene therapy, immunology…

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesenas Chief Medical Officer
Dr. Ottesen brings in-depth global clinical development expertise…

Nordic Bioscience receives Letter of Support from the FDA for the PRO-C3 biomarker in tumor fibrosis
Nordic Bioscience receives Letter of Support from the U.S. Food…

Invizius announces ‘Angry Blood’ Haemodialysis Study and recruits its 300th patient
Novel study is investigating dysregulation of the complement…

Women in Life Science Denmark (WiLD) receives grant from The Lundbeck Foundation to support and advance its Female Leadership Mentoring Program
WiLD is a new and fast-growing professional network for women…

Futura’s Fast-Acting Topical Gel for the Treatment of Erectile Dysfunction Granted Marketing Authorisation by the US FDA for Over the Counter Sale
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a…

Vicore has carried out directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share, raising gross proceeds of SEK 500 million
Stockholm, 9 June 2023 – Vicore Pharma Holding AB (publ) (“Vicore”…

Vicore further strengthens patent protection for C21
Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO:…

Biocomposites adds proprietary NanoBone® technology to its portfolio through the acquisition of Artoss GmbH
NanoBone® technology complements Biocomposites’ absorbable…

Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to acquire Synaffix B.V., an innovative biotech company…

iOnctura To Present Research At Leading Scientific Conferences In June 2023
Geneva, Switzerland and Amsterdam, The Netherlands, 1 June 2023 -…

Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
Acquisition of next generation radiopharmaceutical clinical…

Zephyrus Innovations appoints David Whitaker as Chief Technology Officer
Vancouver, Canada – 30 May 2023: Zephyrus Innovations (Zephyrus),…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York